Axsome Therapeutics (AXSM) Stock Overview
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AXSM from our risk checks.
AXSM Community Fair Values
Create NarrativeSee what 59 others think this stock is worth. Follow their fair value or set your own to get alerts.
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$118.77 |
| 52 Week High | US$139.13 |
| 52 Week Low | US$75.56 |
| Beta | 0.53 |
| 1 Month Change | 2.11% |
| 3 Month Change | 15.79% |
| 1 Year Change | 32.08% |
| 3 Year Change | 154.49% |
| 5 Year Change | 66.69% |
| Change since IPO | 1,258.92% |
Recent News & Updates
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
May 06
R&D Pipeline And NDAs Will Unlock New Approvals
Ongoing R&D and product launch efforts, including key NDA submissions, may significantly enhance future revenues through new product approvals.Recent updates
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
May 06R&D Pipeline And NDAs Will Unlock New Approvals
Ongoing R&D and product launch efforts, including key NDA submissions, may significantly enhance future revenues through new product approvals.Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment?
Apr 15
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Feb 20Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Feb 11After Leaping 59% Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Are Not Flying Under The Radar
Feb 11Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Dec 31Investors Still Waiting For A Pull Back In Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Dec 23Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Nov 29Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Nov 25Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Nov 12Axsome: AXS-07 And Its Upcoming Second PDUFA
Oct 15Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Shareholder Returns
| AXSM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.8% | -1.3% | 0.3% |
| 1Y | 32.1% | -12.5% | 17.4% |
Return vs Industry: AXSM exceeded the US Pharmaceuticals industry which returned -12.7% over the past year.
Return vs Market: AXSM exceeded the US Market which returned 17.6% over the past year.
Price Volatility
| AXSM volatility | |
|---|---|
| AXSM Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXSM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXSM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 846 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| AXSM fundamental statistics | |
|---|---|
| Market cap | US$5.90b |
| Earnings (TTM) | -US$246.90m |
| Revenue (TTM) | US$495.03m |
Is AXSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXSM income statement (TTM) | |
|---|---|
| Revenue | US$495.03m |
| Cost of Revenue | US$42.19m |
| Gross Profit | US$452.85m |
| Other Expenses | US$699.75m |
| Earnings | -US$246.90m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.95 |
| Gross Margin | 91.48% |
| Net Profit Margin | -49.88% |
| Debt/Equity Ratio | 256.6% |
How did AXSM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/24 20:56 |
| End of Day Share Price | 2025/09/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axsome Therapeutics, Inc. is covered by 33 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |